WO2001013885A1 - Method to produce powders for pulmonary or nasal administration - Google Patents
Method to produce powders for pulmonary or nasal administration Download PDFInfo
- Publication number
- WO2001013885A1 WO2001013885A1 PCT/GB2000/003230 GB0003230W WO0113885A1 WO 2001013885 A1 WO2001013885 A1 WO 2001013885A1 GB 0003230 W GB0003230 W GB 0003230W WO 0113885 A1 WO0113885 A1 WO 0113885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drugs
- mixture
- salbutamol
- spray dried
- ipratropium bromide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- This patent relates to a process for preparing combination pharmaceutical formulations for pulmonary or nasal administration.
- the invention also relates to formulations for such uses.
- the invention relates particularly to combinations of drugs used for the treatment of asthma.
- Asthma can be categorised in a number of stages according to official guidelines e.g. British Thoracic Society (Thorax; 1997; 52 (suppl. 5) 51-528);Canadian Thoracic Society (Can Med Assoc. J; 1992; 147: 420 - 8);American Thoracic Society (Am J Respir Crit Care Med; 1995; 152 (suppl) 577 - 5120).
- British Thoracic Society Thorax; 1997; 52 (suppl. 5) 51-528
- Canadian Thoracic Society Can Med Assoc. J; 1992; 147: 420 - 8
- American Thoracic Society Am J Respir Crit Care Med; 1995; 152 (suppl) 577 - 5120.
- Examples of ⁇ 2 agonists are salbutamol, rimiterol, bambuterol, fenoterol, pirbuterol, Isoetharine and terbutaline. Recently long acting ⁇ 2 agonists have been introduced e.g. salmeterol, eformoterol (sometimes known as formoterol).
- Examples of antimuscarinic agents include ipatropium bromide and oxitropium bromide.
- Examples of steroids include beclomethasone esters, fluticasone, budesonide and mometasone.
- combination products include:- a) Short acting ⁇ 2 agonist + antimuscarinic e.g. salbutamol + ipatropium bromide (Duovent®) fenoterol + ipatropium bromide (Combivent®). b) Short acting ⁇ 2 agonist + corticosteroid e.g. salbutamol + beclomethasone (Ventide®). c) Long acting ⁇ 2 agonist + corticosteroid e.g. salmeterol + fluticasone EP (Seretide®) eformoterol + budesonide EP
- Such products can be used normally as aerosols, either for delivery into the lung or nose i.e. as metered dose inhalers, as dry powder inhalers usually for pulmonary use. as pressurised pump solutions for nasal administration or by the use of nebulizers.
- the formulation is a solution then there are few problems with uniformity of dosage apart from those normally associated with such devices e.g. valve design and actuator design.
- the product is formulated as a suspension there are more problems, for example settling of the suspension in the aerosol over time, caking on the sides of the aerosol container or non uniformity of the mixture in dry powder devices.
- the powders have to be a controlled particle size to ensure delivery to the place of action.
- the particle size is normally controlled to a mass mean diameter of 1 - 5 microns.
- ipatropium bromide because the dose can be as low as 20 micrograms per shot; eformoterol where a common dose is 12 micrograms per shot; and salmeterol where a dose of 25 micrograms is often given.
- a pharmaceutical formulation comprises a mixture of two or more drugs optionally together with one or more excipients, the mixture being formed by the steps of: co-crystallisation or co-precipitation of the drugs followed by micronisation or milling to produce a uniform powder having a particle size and other properties suitable for formulation for pulmonary or nasal administration.
- Formulations of this invention may be used to ensure uniform dosing of each drug in a combination and to reduce any physical incompatibilities in suspension.
- the co- crystallisation or co-precipitation of the two components, and subsequent micronisation is used to produce a uniform powder suitable for formulation in pharmaceutical products for pulmonary or nasal administration.
- the preferred method of manufacture may depend on the two (or more) drugs needed for the specific combination product. The following methods may be employed.
- Spray drying is particularly preferred.
- Co-crystallisation of both drugs may be carried out from aqueous or non-aqueous solutions. Uniformity of drug ratio also needs to be ensured.
- An alternative method is the precipitation or crystallisation of one drug onto crystals of another. Co-crystallisation may be carried out using a super critical fluid, for example super critical carbon dioxide. Suitable apparatus is disclosed in GB-A-2322326, GB-A-2334900 and GB-A-2339165.
- the particles of the combined drugs may be subsequently milled or micronised to the appropriate size e.g. 3 - 5 microns for pulmonary inhalation.
- the resultant co-crystallised or co-precipitated drugs have a particle size suitable for inhalation without micronisation.
- Spray drying of salbutamol sulphate and ipratropium bromide from aqueous solutions is particularly advantageous as particles of 3 - 7 ⁇ m may be obtained. These may have smooth configurations suitable for use in inhalation formulators without milling or micronising.
- antioxidants may be added.
- Examples of mixed products include drugs listed in two or more of the columns below.
- All drugs can be present either as bases, salts or esters as appropriate to give the best mixed product, that is a crystalline or amorphous mixture which can be milled or micronised as necessary at ambient temperatures and which is stable on storage.
- Preferred mixtures of drugs include salbutamol sulphate and ipratropium bromide, and salbutamol and ipratropium bromide, eformoterol and a steroid for example beclamethasone fluticasone or budesonide.
- Various ratios of weights may be employed, for example but not limited to 10: 1, 5: 1 and 2: 1.
- a pharmaceutical composition includes a homogeneous mixture of salbutamol and ipratropium bromide comprising crystalline particles.
- a pharmaceutical composition as previously described for manufacture of an aerosol for delivery into the lung or nose.
- Air flow rate 600-700 lhf 1
- Air flow rate 500 lhf 1
- Air flow rate 700 lhf 1
- Air flow rate 500 lhf 1
- the percentage yield was approx 26%.
- Salbutamol BP was spray dried again under similar conditions except that the pump setting was increased to 6. 9g of powder was weighed and spray dried as a 2.5%> w/v solution from ethanol (96%>). The spray drying parameters used were:
- Air flow rate 500 lhf 1
- ipratropium bromide from aqueous solution 5g of ipratropium bromide was spray dried as a 5%> w/v aqueous solution. The spray drying parameters were
- Air flow rate 700 lhf 1 (v) ipratropium bromide from ethanolic solution: ipratropium bromide was spray dried from an ethanolic solution (96%>). lOg in total was spray dried as a 2.5% w/v solution.
- the spray drying parameters were:
- Air flow rate 500 lhf 1
- Air flow rate 600-700 lhf 1
- Air flow rate 700 lhf 1
- Air flow rate 600-700 lhf 1
- the physical characteristics of the spray-dried compounds and mixtures were determined by xray diffraction (XRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier transform infrared (FTI) and scanning electron microscopy (SEM).
- the powder X-Ray Diffractometer used was a Siemens D500 Diffractometer which consist of a DACO MP wide-range goniometer. A 1.00° dispersion slit, a 1.00° anti-scatter slit and a 0.15° receiving slit were used.
- the Cu anode x-ray tube was operated at 40kV and 30mA in combination with a Ni filter to give monochromatic Cu K X-rays. All measurements were taken from 5 to 35 on the 2 theta scale at a step size of 0.05 second.
- the Differential Scanning Calorimeter used was a Mettler Toledo DSC 82 l e , Mettler Toledo STAR e software Version 5.1 with a Solaris operating system. Samples were placed in open (hermetically sealed aluminium with three vent holes) pan types under nitrogen purge. Sample weights were between 5 and lOmg. DSC experiments were run generally from 30 to 250 or 350°C (depending on degradation products) at a heating rate of 10°C/minute. Two DSC scans were obtained from each system.
- Thermogravimetric analysis was carried out using a Mettler TG 50 linked to a Mettler MT5 balance. Data was processed using Mettler Toledo STAR e software Version 5.1 with a Solaris operating system. Sample weights between 5 and 1 Omg were used and analysis carried out under nitrogen purge. The scans were generally run from 30 to 350°C at a heating rate of 10°C/minute. Two TGA scans were obtained for each system.
- the scanning electron microscope used was the Hitachi S-3500N variable pressure scanning electron microscope. Samples were mounted and sputtered with gold spray for SEM. Fourier Transform Infra-red Spectroscopy (FTIR)
- the spectrometer used was a Perkin Elmer Paragon 1000 FTIR.
- KBr discs were prepared based on lmg%> sample loading. Discs were prepared by grinding the sample with KBr in an agate mortar and pestle, placing the sample in an evacuable KBr die and applying 8 tons of pressure in a Graseby Specac IR press. Two FTIR spectra were obtained for each system.
- Salbutamol sulphate as supplied was a crystalline material by XRD.
- XRD X-ray diffraction
- the amorphous material was relatively stable on heating. There was no obvious exotherm in the DSC thermogram, reflective of recrystallisation from the glass.
- the infrared spectrum of the spray dried sample compared to the spectrum of the original material showed a change in the OH region and no match for bands at 1546 and 1244 cm "1 seen in the original spectrum. There was inconsistency in the intensity of some bands between the two spectra.
- Small spherical particles, typical of amorphous material were observed by SEM. Particle diameters ranged from ⁇ l/im to ⁇ 8//m. The surface of the particles was slightly dimpled.
- Spray drying from ethanolic solution also resulted in an amorphous material by XRD. Again the DSC showed no obvious exotherm indicative of recrystallisation. Small spherical particles, typical of amorphous material were observed by SEM. Comparisons of SEMs showed that particles were smaller than those produced from the aqueous solution, with particle diameters less than ⁇ 3 ⁇ m. The surface of the particles was slightly dimpled.
- Salbutamol as supplied was a crystalline material by XRD. On spray drying from ethanolic solute, the XRD indicated the same crystalline form was present, although some peak intensity differences were evident. As the initial conditions used to spray dry the material resulted in a lower yield, the spray drying conditions were adjusted appropriately to improve the yield. A lower inlet temperature, lower pump rate (2 different settings) and decreased flow rate were used. Three spray dried samples were analysed by DSC. The major peak in the DSC occurred at the same position as the melting endotherm of salbutamol base. An exotherm, typical of the presence of an amorphous material that is physically unstable, occurred before the melting endotherm. The position and size of this peak varied between the three samples.
- the energy change associated with the exotherm was lower if the DSC was performed the day after spray drying.
- the exotherm was also at a higher temperature. This suggests that the spray dried material contains some amorphous material which rapidly converted to the crystalline form.
- the infrared spectrum was a good match to the spectrum of the original material. Rough, irregular shaped particles were observed by SEM, with diameters ranging from less than l ⁇ m to ⁇ 8 or 7 ⁇ m.
- Ipratropium bromide as supplied was a crystalline material by XRD.
- the DSC showed a major endotherm with a peak at ⁇ 237°C, which can be attributed to melting. However two further lower temperature overlapping endotherms between 80 and 120°C were also evident. TGA indicated that these lower temperature endotherms represented 3 to 4% to the total solid mass. This suggested the presence of solvent.
- the DSC of the spray dried material showed four endothermic events. There were two low temperature endotherms between about 85 and 120°C.
- the TGA did not detect any mass loss associated with these endotherms and the combined energy change associated with them was ⁇ 4J/g compared to ⁇ 122J/g for the ipratropium bromide original raw material. There was another small endothermic peak at -208 °C before the large melting endotherm. Rough, irregular shaped particles were observed by SEM, with diameters ranging from about 5 to 20 ⁇ m.
- the XRD was very similar to that of the starting material.
- the DSC showed two low temperature endothermic peaks as well as a higher melting endotherm.
- the energy changes associated with the lower temperature endotherms was smaller than that of the low temperature endotherms of the starting material ( ⁇ 49J/g versus 122J/g) and the TGA did not detect any mass loss associated with them.
- the shape of the endotherms was also somewhat different to hose of the starting material.
- the spray dried sample in the IR showed some changes in the OH region relative to the original material. Large crystalline particles were evidence under SEM with diameters of the order of 60 ⁇ m and larger. 01/13885 _i2_
- Salbutamol sulphate ipratropium bromide mixtures on spray drying from aqueous solution gave amorphous materials with physicochemical characterisation (XRD, DSC) similar to the spray dried salbutamol sulphate alone. Both DSC and XRD were similar to those of spray dried salbutamol sulphate. At the three ratios studied, the ipratropium bromide appeared to be dispersed in salbutamol sulphate in an amorphous form.
- XRD physicochemical characterisation
- the infrared spectrum of the 2: 1 system showed some differences in the OH region and a change in intensity of some bands when compared to the equivalent physical mix.
- the spray dried sample showed loss of 1245cm “1 , 1087cm “1 and 1030cm “1 bands and showed new bands at 1508cm “1 , 1268cm “1 , 1044cm “1 and 1003cm "1 . Some other minor inconsistencies were apparent.
- SEM showed particles from all three systems prepared to be small and spherical, typical of amorphous material.
- the 10:1 sample displayed slightly dimpled particles less than 3 ⁇ m in diameter.
- the 5: 1 systems displayed more significantly dimpled particles, with diameters less than 5 ⁇ m.
- the 2:1 system displayed smooth spherical particles with diameters less than 7 ⁇ m.
- the samples were tested for degradation of salbutamol.
- the level of degradants was below the acceptable limits.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001518024A JP2003526629A (en) | 1999-08-20 | 2000-08-21 | Method for producing powder for pulmonary or nasal administration |
CA002382216A CA2382216A1 (en) | 1999-08-20 | 2000-08-21 | Method to produce powders for pulmonary or nasal administration |
AU68529/00A AU6852900A (en) | 1999-08-20 | 2000-08-21 | Method to produce powders for pulmonary or nasal administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15009599P | 1999-08-20 | 1999-08-20 | |
US60/150,095 | 1999-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001013885A1 true WO2001013885A1 (en) | 2001-03-01 |
Family
ID=22533110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003230 WO2001013885A1 (en) | 1999-08-20 | 2000-08-21 | Method to produce powders for pulmonary or nasal administration |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2003526629A (en) |
AU (1) | AU6852900A (en) |
CA (1) | CA2382216A1 (en) |
WO (1) | WO2001013885A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085338A2 (en) * | 2001-04-23 | 2002-10-31 | Pharmascience Inc. | Ipratropium formulation for pulmonary inhalation |
WO2003094892A1 (en) * | 2002-05-07 | 2003-11-20 | Focus Inhalation Oy | Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray dried material in drug formulations |
EP1531866A1 (en) * | 2002-08-29 | 2005-05-25 | Cipla Ltd. | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
EP1646354A2 (en) * | 2003-07-22 | 2006-04-19 | Baxter International Inc. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
JP2006523630A (en) * | 2003-04-16 | 2006-10-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Nasal pharmaceutical preparation and method of use thereof |
WO2007134965A1 (en) * | 2006-05-19 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Aerosol formulation containing ipratropium bromide and salbutamol sulfate |
WO2007134967A1 (en) * | 2006-05-19 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Propellant-free inhalation aerosol formulation containing ipratropium bromide and salbutamol sulfate |
US7972627B2 (en) | 2003-04-16 | 2011-07-05 | Merck Patent Gmbh | Beclomethasone dipropionate monohydrate nasal pharmaceutical formulations and methods of using the same |
US8129364B2 (en) | 2003-04-16 | 2012-03-06 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
CN103930095A (en) * | 2011-08-08 | 2014-07-16 | 普罗索尼克斯有限公司 | Eutectic mixture for pulmonary administration |
US8936813B2 (en) | 2001-11-01 | 2015-01-20 | Novartis Ag | Spray drying methods and related compositions |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US9700529B2 (en) | 2002-05-03 | 2017-07-11 | Nektar Therapeutics | Particulate materials |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
US11304937B2 (en) | 2016-07-12 | 2022-04-19 | Shionogi & Co., Ltd. | Medicinal composition for inhalation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009524646A (en) * | 2006-01-27 | 2009-07-02 | ザ・プロヴォスト,フェローズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホーリー・アンド・アンディヴァイデッド・トリニティー・オブ・クイーン・エリザベス,ニア・ダブリン | Method for producing porous fine particles |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360616A (en) * | 1990-06-14 | 1994-11-01 | Applicaciones Farmaceuticas S.A. De C.V. | Injectable pharmaceutical composition |
WO1998041193A1 (en) * | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation of powder agglomerates |
WO1999048476A1 (en) * | 1998-03-26 | 1999-09-30 | Glaxo Group Limited | Improved compositions for inhalation |
-
2000
- 2000-08-21 WO PCT/GB2000/003230 patent/WO2001013885A1/en active Application Filing
- 2000-08-21 CA CA002382216A patent/CA2382216A1/en not_active Abandoned
- 2000-08-21 AU AU68529/00A patent/AU6852900A/en not_active Abandoned
- 2000-08-21 JP JP2001518024A patent/JP2003526629A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360616A (en) * | 1990-06-14 | 1994-11-01 | Applicaciones Farmaceuticas S.A. De C.V. | Injectable pharmaceutical composition |
WO1998041193A1 (en) * | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation of powder agglomerates |
WO1999048476A1 (en) * | 1998-03-26 | 1999-09-30 | Glaxo Group Limited | Improved compositions for inhalation |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085338A3 (en) * | 2001-04-23 | 2003-04-03 | Pharmascience Inc | Ipratropium formulation for pulmonary inhalation |
WO2002085338A2 (en) * | 2001-04-23 | 2002-10-31 | Pharmascience Inc. | Ipratropium formulation for pulmonary inhalation |
US8936813B2 (en) | 2001-11-01 | 2015-01-20 | Novartis Ag | Spray drying methods and related compositions |
US10945972B2 (en) | 2002-05-03 | 2021-03-16 | Nektar Therapeutics | Particulate materials |
US9700529B2 (en) | 2002-05-03 | 2017-07-11 | Nektar Therapeutics | Particulate materials |
US10188614B2 (en) | 2002-05-03 | 2019-01-29 | Nektar Therapeutics | Particulate materials |
WO2003094892A1 (en) * | 2002-05-07 | 2003-11-20 | Focus Inhalation Oy | Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray dried material in drug formulations |
EP1531866A1 (en) * | 2002-08-29 | 2005-05-25 | Cipla Ltd. | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
US8129364B2 (en) | 2003-04-16 | 2012-03-06 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7972626B2 (en) | 2003-04-16 | 2011-07-05 | Merck Patent Gmbh | Fluticasone propionate nasal pharmaceutical formulations and methods of using same |
US7972627B2 (en) | 2003-04-16 | 2011-07-05 | Merck Patent Gmbh | Beclomethasone dipropionate monohydrate nasal pharmaceutical formulations and methods of using the same |
US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8158154B2 (en) | 2003-04-16 | 2012-04-17 | Dey Pharma, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US8309061B2 (en) | 2003-04-16 | 2012-11-13 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US8663695B2 (en) | 2003-04-16 | 2014-03-04 | Mylan Specialty L.P. | Formulations and methods for treating rhinosinusitis |
JP2006523630A (en) * | 2003-04-16 | 2006-10-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Nasal pharmaceutical preparation and method of use thereof |
JP4680180B2 (en) * | 2003-04-16 | 2011-05-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nasal pharmaceutical preparation and method of use thereof |
US9180126B2 (en) | 2003-04-16 | 2015-11-10 | Mylan Specialty L.P. | Formulations and methods for treating rhinosinusitis |
EP1646354A4 (en) * | 2003-07-22 | 2010-03-17 | Baxter Int | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
EP1646354A2 (en) * | 2003-07-22 | 2006-04-19 | Baxter International Inc. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
WO2007134967A1 (en) * | 2006-05-19 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Propellant-free inhalation aerosol formulation containing ipratropium bromide and salbutamol sulfate |
WO2007134965A1 (en) * | 2006-05-19 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Aerosol formulation containing ipratropium bromide and salbutamol sulfate |
US9238031B2 (en) | 2006-05-19 | 2016-01-19 | Boehringer Ingelheim International Gmbh | Propellant-free aerosol formulation for inhalation |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9220708B2 (en) | 2011-08-08 | 2015-12-29 | Prosonix Limited | Pharmaceutical compositions |
CN103930095A (en) * | 2011-08-08 | 2014-07-16 | 普罗索尼克斯有限公司 | Eutectic mixture for pulmonary administration |
US10220163B2 (en) | 2012-04-13 | 2019-03-05 | Boehringer Ingelheim International Gmbh | Nebuliser with coding means |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10894134B2 (en) | 2013-08-09 | 2021-01-19 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US11642476B2 (en) | 2013-08-09 | 2023-05-09 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10716905B2 (en) | 2014-02-23 | 2020-07-21 | Boehringer Lngelheim International Gmbh | Container, nebulizer and use |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
US11304937B2 (en) | 2016-07-12 | 2022-04-19 | Shionogi & Co., Ltd. | Medicinal composition for inhalation |
Also Published As
Publication number | Publication date |
---|---|
AU6852900A (en) | 2001-03-19 |
JP2003526629A (en) | 2003-09-09 |
CA2382216A1 (en) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001013885A1 (en) | Method to produce powders for pulmonary or nasal administration | |
US20020081266A1 (en) | Spray dried powders for pulmonary or nasal administration | |
EP2560620B1 (en) | A process for particle processing of active pharmaceutical ingredients | |
US6030604A (en) | Formulation for inhalation | |
JP2978247B2 (en) | Material Conditioning Method | |
AU2008334547B2 (en) | Organic compounds | |
SK284919B6 (en) | Method of producing powder agglomerates and dosage form comprising thereof | |
CN1430508A (en) | Novel composition | |
Corrigan et al. | Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers | |
EP1572153B1 (en) | Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation | |
JP6940416B2 (en) | Multi-agent brittle matrix composition | |
PL199420B1 (en) | Medicinal aerosol formulations | |
UA120418C2 (en) | Particle size reduction of an antimuscarinic compound | |
US20100247658A1 (en) | Organic compounds | |
RU2470639C2 (en) | Inhalation compositions containing monteleukast acid and pde-4 inhibitor or inhalation corticosteroid | |
CN106604720A (en) | Formulation comprising glycopyrrolate, method and apparatus | |
AU754074B2 (en) | A method for making a pharmaceutical formulation | |
CN106163505B (en) | Improvements relating to inhalable particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 68529/00 Country of ref document: AU Ref document number: 2382216 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027002185 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020027002185 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |